112808-55-6

Basic information

• Product Name: Butanamide, 2-bromo-N-[2-hydroxy-3-(1-methylethyl)phenyl]-3-methyl-
• CAS NO: 112808-55-6
• Molecular Formula: C14H20BrNO2
• Molecular Weight: 314.222
• Mol File: 112808-55-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Butanamide, 2-bromo-N-[2-hydroxy-3-(1-methylethyl)phenyl]-3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanamide, 2-bromo-N-[2-hydroxy-3-(1-methylethyl)phenyl]-3-methyl-(112808-55-6)
• EPA Substance Registry System: Butanamide, 2-bromo-N-[2-hydroxy-3-(1-methylethyl)phenyl]-3-methyl-(112808-55-6)

Safety Data

• Hazardous Substances Data: 112808-55-6(Hazardous Substances Data)

Upstream product

• 27109-47-3 2-bromoisovaleryl chloride 
• 127293-44-1 4-bromo-2-isopropyl-6-nitrophenol 
• 26307-50-6 4-bromo-2-isopropyl-phenol 
• 10323-40-7 2-bromoisovaleric acid 
• 88-69-7 2-(1-methylethyl)phenol 
• 29078-20-4 2-Amino-6-isopropylphenol 

Downstream Products

• 112808-22-7 AD 5467 

Relevant articles and documents

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

Studies on antidiabetic agents. IX. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives: Synthesis and biological activity

-